UCSF study finds psilocybin may reduce inflammation in Parkinson's patients

A recent study conducted by researchers at the University of California, San Francisco, found that psilocybin, a classic psychedelic, may help reduce inflammation in people with Parkinson's disease. The research, published in JAMA Psychiatry, is among the first to provide human data suggesting psychedelics could have therapeutic potential beyond mental health.

The UCSF team measured five different signaling molecules related to inflammation in participants before and after two psilocybin sessions. They observed significantly lower levels of inflammation following treatment, with these reductions persisting a month after the last dose. This aligns with previous lab studies on animals and cell models.

In addition to inflammation markers, the study tracked a blood marker of mitochondrial stress, which showed substantial improvement immediately after psilocybin administration, though these effects were not sustained in the longer term.

The findings point to the possibility that psychedelics like psilocybin may help combat diseases characterized by inflammation and immune dysregulation, potentially offering new avenues for treating neurodegenerative conditions such as Parkinson's disease.

Further research is needed to confirm these results and understand the mechanisms involved, but this study provides an initial biological basis for exploring psychedelics as treatments for inflammation-related illnesses.